JP2025508337A5 - - Google Patents
Info
- Publication number
- JP2025508337A5 JP2025508337A5 JP2024544912A JP2024544912A JP2025508337A5 JP 2025508337 A5 JP2025508337 A5 JP 2025508337A5 JP 2024544912 A JP2024544912 A JP 2024544912A JP 2024544912 A JP2024544912 A JP 2024544912A JP 2025508337 A5 JP2025508337 A5 JP 2025508337A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303577P | 2022-01-27 | 2022-01-27 | |
| US63/303,577 | 2022-01-27 | ||
| PCT/CA2023/050096 WO2023141710A1 (en) | 2022-01-27 | 2023-01-26 | Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508337A JP2025508337A (ja) | 2025-03-26 |
| JP2025508337A5 true JP2025508337A5 (https=) | 2026-02-03 |
| JPWO2023141710A5 JPWO2023141710A5 (https=) | 2026-02-03 |
Family
ID=87469898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544912A Pending JP2025508337A (ja) | 2022-01-27 | 2023-01-26 | 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250114464A1 (https=) |
| EP (1) | EP4469576A4 (https=) |
| JP (1) | JP2025508337A (https=) |
| CN (1) | CN119137274A (https=) |
| CA (1) | CA3243078A1 (https=) |
| WO (1) | WO2023141710A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9801948B2 (en) * | 2011-09-21 | 2017-10-31 | Yale University | Antimicrobial compositions and methods of use thereof |
| US20220288218A1 (en) * | 2019-07-09 | 2022-09-15 | The Governors Of The University Of Alberta | Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene |
| US20230048338A1 (en) * | 2019-12-20 | 2023-02-16 | PYC Therapeutics Limited | Novel cellular delivery methods |
-
2023
- 2023-01-26 US US18/730,955 patent/US20250114464A1/en active Pending
- 2023-01-26 WO PCT/CA2023/050096 patent/WO2023141710A1/en not_active Ceased
- 2023-01-26 JP JP2024544912A patent/JP2025508337A/ja active Pending
- 2023-01-26 CN CN202380028701.3A patent/CN119137274A/zh active Pending
- 2023-01-26 CA CA3243078A patent/CA3243078A1/en active Pending
- 2023-01-26 EP EP23745765.0A patent/EP4469576A4/en active Pending